PDS Biotechnology Earnings Call Transcripts
Fiscal Year 2026
-
The 2026 annual meeting was held virtually, covering director elections, governance amendments, auditor ratification, and executive compensation. All proposals passed, a quorum was confirmed, and no shareholder questions were raised. Forward-looking risks were acknowledged.
-
Clinical programs advanced with protocol amendments expected to accelerate timelines and reduce costs. Net loss narrowed year-over-year, and new patents extend exclusivity into the 2040s. Additional data from colorectal cancer trials anticipated by year-end.
Fiscal Year 2025
-
Clinical programs advanced with a key protocol amendment for faster regulatory submission in HPV-16 positive cancer. Net loss narrowed to $34.5M in 2025, with reduced operating expenses and strong cash position. New patents extend exclusivity into the 2040s.
-
Strong phase 2 survival data in HPV-16 positive head and neck cancer led to a protocol amendment in the phase 3 trial, aiming to accelerate regulatory submission. Net loss narrowed year-over-year, and recent capital raise supports ongoing development.
-
Advanced phase III trial for HPV16-positive head and neck cancer, supported by durable phase II results and strong investigator engagement. Q2 2025 net loss was $9.4M, with reduced operating expenses and a $31.9M cash balance. Final phase II data expected by year-end.
-
HPV 16 positive head and neck cancer incidence is rising, with current therapies often inadequate. The VERSATILE-002 trial showed promising survival and response rates for pembrolizumab plus PDS0101, leading to the ongoing phase III VERSATILE-003 trial. A companion diagnostic and first-line positioning are expected.
-
VERSATILE-002 phase two results show a median overall survival of 30 months for HPV16 positive head and neck cancer, far exceeding historical controls. The ongoing VERSATILE-003 phase three trial uniquely targets this high-risk group with a companion diagnostic and strong site support.
-
Versamune HPV, a T-cell immunotherapy, is showing strong survival and tumor response in HPV-16 positive head and neck cancer, with phase III trials underway and significant market potential. Additional pipeline programs, including a MUC1-targeted therapy, are advancing in collaboration with the NCI.
-
Initiated a pivotal phase 3 trial for HPV16-positive head and neck cancer, reporting improved financials with a reduced net loss and strong cash position. Upcoming data updates and collaborations with major research institutions support continued pipeline progress.
-
Versamune HPV plus Keytruda shows promising efficacy and safety in HPV-16 positive head and neck cancer, with a median overall survival of 30 months and strong tumor response rates. The ongoing phase 3 trial aims to confirm these results, while academic partnerships and recent fundraising support continued development.
Fiscal Year 2024
-
Initiated phase III VERSATILE-003 trial in HPV16-positive head and neck cancer, supported by strong phase II data and FDA-approved design. Net loss narrowed to $37.6M in 2024, with $41.7M cash at year-end and a $22M direct offering in early 2025. Funding for the trial will be raised in stages.
-
Investor and investigator interest remains strong for the updated VERSATILE-003 phase III trial, which is set to begin in Q1 2025 with interim data expected about two years later. Q3 2024 net loss improved slightly year-over-year, and the company ended the quarter with $50 million in cash.
-
Received FDA support to initiate a phase III trial of Versamune HPV plus pembrolizumab in HPV16 positive head and neck cancer, following strong phase II data showing deep and durable responses and a median overall survival of 30 months. The market opportunity is estimated at $1.5-$2.3 billion.